PT-141 dosage, half-life and effect duration

Labelled PT-141 dosage

PT-141 dosage for women in the US prescribing information for bremelanotide injection is 1.75 mg subcutaneous as needed, at least 45 minutes before anticipated sexual activity, for acquired, generalized HSDD in premenopausal women. It limits exposure to no more than one dose per 24 hours and no more than 8 doses per month. These are the label's conditions; this page cannot select an amount or schedule for an individual.

I read those limits alongside the cardiovascular and pigmentation warnings, because they were written for a particular medicine and population. FDA approval excludes men, postmenopausal women, erectile dysfunction and performance enhancement. Research-chemical material is for laboratory research and carries none of that pharmaceutical approval.

Dose-finding and route changes

Subcutaneous Phase 2 dose-finding in women used 0.75 mg, 1.25 mg and 1.75 mg. The pivotal RECONNECT program used 1.75 mg as needed. These study amounts describe how the clinical program arrived at its tested formulation.

The earlier male erectile-response program explored intranasal delivery, with escalation to roughly 7-20 mg and a statistically significant erectile response above 7 mg. Drug exposure through the nasal route proved variable, and that route was discontinued. I give the change in route considerable weight when comparing old papers: the numbers came from different delivery conditions and cannot be exchanged as if they described the same exposure.

Phase 1 metabolic studies in obese premenopausal women used high-frequency research exposure to examine appetite and weight. Those experiments concerned a separate pharmacological question. They establish no approved weight-loss use.

PT-141 half-life and pharmacokinetics

The label reports a terminal half-life of approximately 2.7 hours after subcutaneous administration, with a range of 1.9-4.0 h. Median Tmax, the time to peak blood concentration, is about 0.5-1.0 h. Early intranasal studies reported a terminal half-life of 1.85-2.09 h.

The label also gives volume of distribution of approximately 25.0 L, clearance of approximately 6.5 L/hr and serum protein binding of around 21%. Metabolism occurs through hydrolysis of peptide amide bonds and peptidase digestion. In the radiolabeled-dose findings, renal excretion was 64.8% and fecal excretion 22.8%. The LiverTox monograph also describes amide-bond hydrolysis and minimal drug-drug interactions.

PT-141 duration

The half-life describes the concentration decline in blood. The fMRI crossover study observed increased sexual desire for up to 24 hours in its HSDD population. Those observations concern different things, so the 2.7-hour figure cannot serve as a personal countdown for desire.

The gap between blood concentration and subjective effect still puzzles me. A continuing downstream response is consistent with the central mechanism, but the available findings offer no reliable clock for an individual. Anecdotal accounts of delayed onset and a long window are discussed on the reports page, with no schedule attached to them.